Study on 22q11 Deletion Syndrome
We are conducting a study in teens and adults of a genetic condition called 22q11.2 deletion syndrome (22q11.2DS). This project aims to better understand how differences in genes affect brain development and behavior including speech, learning, and thinking. In our study, we use tests of cognition and behavior to examine areas of overlap between autism and schizophrenia. We also measure emotional reactions using psychophysiology to look for links to our behavioral measures. Finally, we are developing stem cell derived neurons from our study participants that will allow us to look at how 22q11.2DS influences how cells exchange information in the brain. We are looking for people who have 22q11.2DS to participate in the study. Participation in the study involves an approximate 10-hour time commitment that is spread across two days of visits. Participants receive $100 of compensation for each study visit. Travel arrangements may be provided for participants with 22q11.2 deletion syndrome who would be traveling out of state. For more information about this study, or to find out how to volunteer, please contact our team at 470-895-5056 or 404-561-8408.
Principal Investigators: Erica Duncan, MD & Joe Cubells, MD, PhD
Research Facility: Emory University and Atlanta VA Health Care System
A Study to Assess the Effects of RO6889450 (Ralmitaront) in Participants With Schizophrenia or Schizoaffective Disorder and Negative Symptoms
This study investigates the effects of RO6889450 on the negative symptoms associated with schizophrenia and schizoaffective disorder.
Learn more about this study.
Multimodal study of depression, schizophrenia, and normal controls
PI Gari Clifford